Welcome to our dedicated page for Keros Therapeutics SEC filings (Ticker: KROS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Keros Therapeutics, Inc. (Nasdaq: KROS) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on Keros’ clinical programs, capital allocation decisions, governance changes and financial condition.
As a clinical-stage biopharmaceutical company focused on TGF-ß pathway therapeutics, Keros uses its SEC filings to report material events related to its lead product candidate KER-065 and its most advanced candidate elritercept. Form 8-K reports have covered topics such as additional clinical data from a Phase 1 trial of KER-065, U.S. Food and Drug Administration Orphan Drug designation for KER-065 in Duchenne muscular dystrophy, and corporate updates regarding the prioritization of KER-065 and discontinuation of internal development of cibotercept (KER-012).
Filings also document Keros’ capital return program and share repurchase activity. Recent 8-Ks describe stock purchase agreements with entities affiliated with ADAR1 Capital Management and Pontifax Venture Capital, the planned and completed cash tender offer to repurchase a substantial number of shares of common stock at a fixed price, and related governance changes. Other reports furnish quarterly financial results, including revenue from a global license agreement with Takeda Pharmaceuticals U.S.A., Inc. related to elritercept, research and development spending and cash and cash equivalents.
On this page, users can review real-time updates as new KROS filings are posted to EDGAR, including Forms 8-K, 10-Q and 10-K when available, as well as exhibits such as press releases and corporate presentations. Stock Titan’s AI-powered tools summarize lengthy filings, highlight key sections and help explain complex topics like capital return structures, executive employment agreements and risk factor disclosures in more accessible language.
For those analyzing Keros’ development strategy, financial runway, licensing arrangements or governance, the SEC filings page serves as a primary source of company-sanctioned information. It allows investors and researchers to trace how Keros reports progress on its TGF-ß–focused pipeline, documents material agreements and communicates significant corporate events over time.
Lerner Lorena Raquel reported acquisition or exercise transactions in this Form 4 filing.
Keros Therapeutics Chief Scientific Officer Lorena Raquel Lerner received a grant of 75,000 employee stock options on February 24, 2026. These options were awarded at no cost as part of her compensation and increase her directly held derivative securities to 75,000.
One-fourth of the option grant will vest on February 24, 2027, with the remaining options vesting in twelve substantially equal quarterly installments after that date, so long as she continues to provide services to the company through each vesting date.
Keros Therapeutics, Inc. appointed Charles Newton to its Board of Directors as a Class III director, effective March 9, 2026, with his term expiring at the 2026 annual meeting of stockholders. He will also serve on the Compensation and Audit Committees.
Newton will receive the company’s standard non-employee director compensation, including an initial stock option grant and an initial restricted stock unit award, each with a grant date fair value of $150,000, plus ongoing annual equity awards with grant date fair values of $75,000 each. He will also receive annual cash retainers totaling $57,000 for his Board and committee service and will enter into Keros’ standard indemnification agreement.
Carl Gordon, Ph.D., CFA, notified the Board of his resignation, effective March 9, 2026. The company states his resignation is not due to any disagreement regarding its operations, policies or practices. Keros concurrently updated the composition of its Audit, Compensation and Nominating and Corporate Governance Committees.
Keros Therapeutics chief executive officer Jasbir Seehra reported an open-market sale of 7,015 shares of common stock on
According to the disclosure, this was an automatic "sell-to-cover" transaction to satisfy tax withholding obligations triggered by the vesting of restricted stock units, and was not executed at his discretion.
Keros Therapeutics Chief Science Officer Lorena Raquel Lerner reported an automatic sale of 3,873 shares of common stock on February 18, 2026. The issuer has a “sell-to-cover” policy, so these shares were sold solely to cover tax withholding on vesting restricted stock units.
The open-market sale occurred at a weighted average price of $16.35 per share, with individual trades ranging from $16.05 to $16.65. After this tax-related transaction, Lerner directly held 31,127 shares of Keros Therapeutics common stock.
Keros Therapeutics SVP and General Counsel Esther Cho reported an automatic sale of 4,745 shares of common stock. The shares were sold in open-market transactions at a weighted average price of $16.35 per share, with individual trade prices ranging from $16.05 to $16.65.
According to the disclosure, Keros Therapeutics has a “sell-to-cover” policy for tax withholding, and these sales reflect shares sold to satisfy Ms. Cho’s tax obligations upon vesting of restricted stock units. The filing notes the sales were automatic and not at her discretion. After the transactions, she beneficially owned 39,755 shares, including 500 shares acquired under the company’s 2020 Employee Stock Purchase Plan.
Keros Therapeutics, Inc. chief financial officer Keith Regnante reported an automatic open-market sale of common stock tied to tax withholding on vested restricted stock units. He sold 4,739 shares on February 18, 2026 at a weighted average price of $16.35 per share, in multiple trades between $16.05 and $16.65. After these sell-to-cover transactions, he beneficially owns 39,261 shares of Keros Therapeutics common stock directly.
Keros Therapeutics, Inc. announced that President and CEO Jasbir S. Seehra will present at three upcoming healthcare investor conferences. He is scheduled for a corporate presentation at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, and a fireside chat at the Leerink Partners Global Healthcare Conference on March 10, 2026, all in Eastern time. Webcast links are provided, and replays will be available in the Investors section of Keros’ website for up to 90 days after each event. Keros is a clinical-stage biopharmaceutical company developing protein therapeutics targeting dysfunctional signaling of the TGF-ß family of proteins, with lead candidates rinvatercept (KER-065) for Duchenne muscular dystrophy and amyotrophic lateral sclerosis, and elritercept for cytopenias in myelodysplastic syndrome and myelofibrosis.
Keros Therapeutics, Inc. received an updated ownership report from ExodusPoint-related entities. As of December 31, 2025, ExodusPoint Capital Management, LP, ExodusPoint Capital Partners GP, LLC, and Michael Gelband together may be deemed to beneficially own 13,360 shares of Keros common stock, representing approximately 0.04% of the outstanding shares.
The shares are held directly by ExodusPoint Partners Master Fund, LP, while ExodusPoint Capital Management has investment and voting power under an investment management agreement. ExodusPoint Capital Partners is the general partner of ExodusPoint Capital Management, and Gelband controls both entities. The filers certify that the securities are not held to change or influence control of Keros.
Madison Avenue International LP and affiliated entities reported a passive ownership stake in Keros Therapeutics, Inc. common stock. As of February 17, 2026, they beneficially owned 823,707 shares of Common Stock, representing about 2.7% of the company, based on 30,466,069 shares outstanding as of October 31, 2025.
The filing lists Madison Avenue International LP, Madison Avenue Partners, LP, EMAI Management, LLC, Madison Avenue GP, LLC, Caraway Jackson Investments LLC and Eli Samaha, who may each be deemed beneficial owners through their roles in the investment structure. They certify the shares are not held to change or influence control of Keros Therapeutics.
Keros Therapeutics, Inc. received an amended ownership report showing that Tang Capital and related entities no longer hold any of its common stock. The Schedule 13G/A (Amendment No. 1) reports that Tang Capital Management, Kevin Tang, and affiliated funds beneficially own 0 shares, representing 0% of the Keros common stock class as of the event date of 12/31/2025. The filing also confirms they have no sole or shared voting or dispositive power over any Keros shares and certifies the holdings are not intended to influence control of the company.